logo
Plus   Neg
Share
Email

Amgen: ABP 798 Shows Clinical Equivalence To Rituxan In Clinical Study

Amgen (AMGN) and Allergan plc (AGN) said a clinical study demonstrated clinical equivalence of ABP 798 to Rituxan in patients with CD20-positive B-cell non-Hodgkin's lymphoma. In the study, the overall response rate by week 28 was within the prespecified margin for ABP 798.

Safety and immunogenicity of ABP 798, a biosimilar candidate, were comparable to Rituxan. The comparative clinical study was the second of two studies to support regulatory submissions for ABP 798.

In 2011, Amgen and Allergan plc formed a collaboration to develop and commercialize oncology antibody biosimilar medicines.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The U.S. Food and Drug Administration has granted accelerated approval to Tazverik for the treatment of adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection. Epithelioid sarcoma is a rare sub-type of soft... STIHL recalls about 16,400 STIHL RE 90 pressure washers due to injury hazard. According to the company, the recalled pressure washer nozzle can disconnect from the spray wand when under pressure during use, posing an injury hazard. STIHL said it received seven reports of the nozzle detaching from... CVS Health Corp. launched 13 new HealthHUB locations in CVS Pharmacy stores across Philadelphia and South New Jersey. The healthcare company said it developed the HealthHUB store format to help people manage chronic conditions more conveniently and affordably. The store also features health and wellness products, clinical services and expertise.
Follow RTT
>